Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
Barinthus Biotherapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies that harness the human immune system to treat cancer and certain infectious diseases. The company operates within the biotechnology and biopharmaceutical industries, with a primary emphasis on T cell–based therapeutic platforms designed to induce potent and durable immune responses. Barinthus does not currently market approved products; its activities are centered on research, clinical development, and strategic collaborations.
The company’s core value proposition lies in its proprietary T cell immunotherapy platforms, which are designed to generate high-avidity CD8 and CD4 T cell responses against disease-specific targets. Formerly known as Scancell Holdings plc, the company rebranded as Barinthus Biotherapeutics plc to reflect its broader ambition to develop immune-modulating therapies beyond oncology. Founded in 1997, the company has evolved from an academic spin-out into a publicly listed, clinical-stage biotechnology firm with multiple programs in development.
Business Operations
Barinthus Biotherapeutics conducts its operations primarily through its wholly owned subsidiary, Scancell Limited, which houses its research, development, and clinical activities. The company’s business is organized around proprietary immunotherapy platforms, including SCIB and Modi-1, which are designed to stimulate targeted T cell responses against tumor-associated antigens. These platforms underpin its oncology pipeline, with candidates in clinical trials for indications such as melanoma and other solid tumors.
The company generates revenue primarily from research grants, tax credits, and, where applicable, collaboration or licensing income rather than from product sales. Operations are primarily based in the United Kingdom, with clinical trials conducted in collaboration with hospitals and research centers. As a clinical-stage company, Barinthus retains intellectual property rights to its core technologies and manages development internally, supplemented by contract research organizations and academic partnerships.
Strategic Position & Investments
Strategically, Barinthus Biotherapeutics is focused on advancing its lead immunotherapy candidates through clinical development while preserving optionality for future partnerships or licensing transactions. Growth initiatives center on expanding clinical data for its lead assets, broadening the application of its T cell platforms, and exploring combination approaches with other immuno-oncology agents. The company has historically emphasized capital efficiency and non-dilutive funding where possible.
Barinthus has not disclosed a large portfolio of subsidiaries or diversified investments; instead, it maintains a focused pipeline strategy. Its primary investments are directed toward clinical trials, manufacturing development, and intellectual property protection. The company is also involved in emerging areas of immunotherapy research, including the targeting of post-translationally modified antigens, which it believes may offer differentiation versus existing immuno-oncology approaches.
Geographic Footprint
Barinthus Biotherapeutics is headquartered in the United Kingdom, with its principal offices and laboratories located in Nottingham, England. This location anchors its research and development activities and reflects its origins as a UK-based academic spin-out. The company’s corporate structure and primary operating subsidiary are UK-based.
Internationally, Barinthus has an operational footprint through clinical trial activity and capital markets access rather than physical offices. Its securities are traded in the United States through a Nasdaq listing, providing access to U.S. investors and the global biotechnology investment community. Clinical development activities extend across Europe and may include sites in North America, depending on trial design and regulatory strategy.
Leadership & Governance
Barinthus Biotherapeutics is led by a management team with scientific and operational experience in immunology and biotechnology. The company’s leadership emphasizes rigorous science, disciplined capital allocation, and the translation of academic innovation into clinically meaningful therapies. Governance follows UK public company standards, with oversight from a board comprising executive and non-executive directors.
Key executives include:
- Lindy Durrant – Chief Executive Officer
- Lindy Durrant – Founder and Chief Scientific Officer
- Melanie Toyne – Chief Financial Officer
- David Glover – Non-Executive Chairman
The leadership team’s strategic vision centers on advancing differentiated immunotherapies through clinical validation while positioning the company for potential strategic partnerships or later-stage development opportunities.